Document is current
Any future updates will be listed below
-
Authors
Miltz, Ada R.
Lampe, Fiona C.
Bacchus, Loraine J.
McCormack, Sheena
Dunn, David
White, Ellen
Rodger, Alison
Phillips, Andrew N.
Sherr, Lorraine
Clarke, Amanda
McOwan, Alan
Sullivan, Ann
Gafos, Mitzy
-
Funding
Funding for this research was provided by:
Medical Research Council (MRC_UU_12023/23, MRC_UU_12023/23)
- License Information
-
More Information
Article History
Received: 23 August 2018
Accepted: 8 April 2019
First Online: 25 April 2019
Ethics approval and consent to participate
: The study was reviewed and approved by London Bridge Research Ethics Committee (12/LO/1289). Written informed consent was obtained from all participants.
: Not applicable.
: The PROUD study was provided drug free of charge by Gilead Sciences plc. which also distributed it to participating clinics and provided funds for additional diagnostic tests for HCV and drug levels. AP has received payments for presentations made at meetings sponsored by Gilead in spring 2015. EW has had tuition fees and a stipend paid by Gilead. AC received advisory board fees from Gilead Sciences plc. and GSK/ViiV; speaker fees from Gilead and conferences bursaries from Gilead & Janssen. SM reports grants from the European Union H2020 scheme, EDCTP 2, the National Institute of Health Research, and Gilead Sciences; other support from Gilead Sciences, and the Population Council Microbicide Advisory Board; and is Chair of the Project Advisory Committee for USAID grant awarded to CONRAD to develop tenofovir-based products for use by women (non-financial).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
